Malignancy and IgG4-related disease: the incidence, related factors and prognosis from a prospective cohort study in China

Hanqi Tang1,2, Huaxia Yang1,2*, Panpan Zhang1,2, Di Wu1,2, Shangzhu Zhang1,2, Jiuliang Zhao1,2, Linyi Peng1,2, Hua Chen1,2, Yunyun Fei1,2, Xuan Zhang1,2, Yan Zhao1,2, Xiaofeng Zeng1,2, Fengchun Zhang1,2 & Wen Zhang1,2*

This prospective cohort study aims to investigate the incidence, related factors and prognosis of IgG4-related disease (IgG4-RD) with malignancies in the Chinese cohort. We prospectively analyzed the IgG4-RD patients recruited in Peking Union Medical College Hospital from January 2011 to August 2018 and identified patients diagnosed with IgG4-RD complicating malignancies. Data regarding demographics, clinical features, treatment and prognosis of IgG4-RD patients complicating malignancies were collected and compared to those of age- and sex-matched controls. Among the 587 Chinese patients with IgG4-RD, 17 malignancies were identified. Ten of them developed malignancy after the diagnosis of IgG4-RD, given a standard incidence ratio (SIR) of 2.78 (95%CI 1.33–5.12). Multivariate logistic analysis indicated that autoimmune pancreatitis (OR = 6.230, 95%CI 1.559–24.907, p = 0.010) was positively associated with malignancy, whereas eosinophilia (OR = 0.094, 95%CI 0.010–0.883, p = 0.039) was negatively related with malignancies. During a median follow-up period of 61.4 ± 26.4 months, all patients with IgG4-RD and malignancies survived. We conclude that an increased incidence of malignancy was found in Chinese IgG4-RD cohort. Autoimmune pancreatitis is a potential risk factor, whereas eosinophilia is a possible protective factor for complicating malignancies.

ImmunoglobulinG4-related disease (IgG4-RD) is an immune-mediated fibroinflammatory condition that is typically diagnosed by clinicopathological presentations of enlarged organs, elevation of serum concentrations of IgG4 and pathological findings such as a typical dense lymphoplasmacytic infiltration enriched in IgG4-positive plasma cells, storiform fibrosis, and obliterative phlebitis1–3. Their mass-like clinicopathological presentations and radiologically 18F-FDG-avid hypermetabolic lesions has made it to be one of the great malignancy mimickers2. Previous studies have reported that a spectrum of malignancies occur in association with IgG4-RD, including solid tumors located in the lung, pancreas, gastrointestinal tract, and prostate, as well as lymphoma3–10. Moreover, it is difficult for clinicians to make a diagnosis of IgG4-RD because it can manifest as mass lesions, leading to an occasional misdiagnosis of malignancy. The relationships between these two diseases remain unclear and are the subject of on-going research. However, the mechanism underlying the co-occurrence of IgG4-RD and malignancies has not been fully determined to date.

Wallace reported an increased standardized prevalence ration of malignancy history in IgG4-RD patients5, while studies from Asia, Europe and America have also suggested an increased standardized incidence ratio of malignancy in patients with IgG4-RD3,4,6,7,9,10. However, one study from Japan reported no significant increase in the risk of malignancy8. No epidemiological data for malignancies in Chinese IgG4-RD patients is available. It is also important to know the risk factors and prognosis for IgG4-RD patients harboring malignancies.

Our team at Peking Union Medical College Hospital (PUMCH) established an IgG4-RD cohort in 2011. In previous studies, we prospectively described the clinical characteristics11, sex disparities12, radiographic presentation13 and histopathologic features14 of patients with IgG4-RD in our cohort. The present study focused on the
association between IgG4-RD and malignancies. We sought to describe the incidence and clinical characteristics of malignancies in patients with IgG4-RD. Based on these results, significant factors were evaluated to determine whether they were related to malignancy. Treatments and survivals were also generated to characterize the prognosis.

Methods

Patients and controls. We consecutively collected data on patients with IgG4-RD and malignancies who were prospectively enrolled in the IgG4-RD cohort in PUMCH from January 2011 and June 2018. IgG4-RD was diagnosed according to the 2011 comprehensive diagnostic criteria for IgG4-RD. Malignancies were diagnosed histopathologically by biopsy or resected specimens according to the International Classification of Disease (ICD-10) criteria. Patients with IgG4-RD and malignancy diagnosed at the same time were defined as malignancy diagnosis within 1 year’s duration of IgG4-RD diagnosis. Patients with malignancy history or newly diagnosed malignancy were defined as >1 year before or after the diagnosis of IgG4-RD. To identify the risk factors for malignancies in patients with IgG4-RD, We randomly selected sex and age match IgG4-RD patients without malignancies as controls at a ratio of 3:1 from our cohort. This study was approved by the Medical Ethics Committee of Peking Union Medical College Hospital (No. S-K412) and was complied with all ethics committee requirements. Written informed consent were obtained from all patients and/or their legal guardians.

Data collection. Baseline data concerning demographics, past medical and personal histories, organ involvement and laboratory findings were recorded. Past medical histories included allergy, smoking histories. Laboratory findings were obtained from individual patients when they first diagnosed with IgG4-RD at our institution. Treatments for both IgG4-RD and malignancies were documented. All patients recruited in our cohort were consecutively followed-up in our rheumatology clinic every 3 to 6 months. Death and causes of death were determined by direct contact with the attending clinician or reported by telephone followed-up.

Statistical analysis. The standardized incidence rate (SIR) was calculated by dividing the observed newly developed malignant rate by the expected rate. Expected malignancies were calculated by age-stratified malignancy incidence (cases per 100000 person-year) in general Chinese population multiplying the corresponding number of patients in each age-group. The data of sex- and age-stratified cancer incidence in general population were published before by the Chinese National Cancer Center. Continuous variables were summarized as the means ± standard deviation (SD) or medians and interquartile range (IQR), and categorical data were presented as frequencies (percentages). The Wilcoxon rank sum test and chi-squared tests for independence were utilized to evaluate significant differences in continuous data and categorical data, respectively. To identify risk factors for malignancy in IgG4-RD patients, univariate and stepwise multivariate logistic regression analyses were performed. All statistical analyses were performed with SPSS software (version 23.0).

Results

Demographics of IgG4-RD patients complicating with malignancy. A total of 587 IgG4-RD patients in the PUMCH cohort were consecutively enrolled in this study. Seventeen patients were identified as having malignancies (Table 1, Fig. 1). Among these IgG4-RD with malignancy patients, 11 (64.7%) were male and 6 (35.3%) were female, with mean disease duration of 56.8 ± 13.0 years at the diagnosis of IgG4-RD and 57.5 ± 12.7 years at the diagnosis of malignancy.

Malignancy distribution and SIR. There were 4 (23.5%) patients reported a previous history of malignancy, and the other 13 (76.5%) patients developed malignancies at or after the diagnosis of IgG4-RD. According to the 2011 comprehensive diagnostic criteria for IgG4-RD, 8 (47.1%), 8 (47.1%) and 1 (5.8%) case were diagnosed as definite, probable and possible IgG4-RD cases, respectively (Fig. 1). One (5.9%) patient was diagnosed with lymphoma, and 16 (94.1%) patients had solid tumours. Four (23.5%) patients developed tumours in the gastrointestinal tract. The remaining solid tumours were located in the thyroid (3, 17.6%), renal (2, 11.7%), breast (2, 11.7%), and skin (1, 5.9%), lung (1, 5.9%), uterus (1, 5.9%), prostate (1, 5.9%), lipoblastoma (1, 5.9%), respectively.

There was a significantly increased SIR of total malignancies (2.78, 95% CI 1.33–5.12) in this Chinese cohort. Figure 2 summarized the incidence ratio or prevalence ratios of malignancies in IgG4-RD patients from studies in different nations, including Japan, the UK, the US and South Korea.

Clinical characteristics. Baseline clinical characteristics in patients with and without malignancies were compared as shown in Table 2. IgG4-RD complicating malignancies were less likely to have head and neck involvement (47.1% versus 74.5%, p = 0.036), including dacryoadenitis (41.2% versus 49.0%, p = 0.575), sialadenitis (41.2% versus 56.9%, p = 0.262), thyroiditis (0.0% versus 3.9%, p = 0.407) and sinusitis (11.8% versus 25.4%, p = 0.237). Gastrointestinal tract involvement was found more frequently in patients with IgG4-RD complicating malignancy than in controls (64.7% versus 29.4%, p = 0.010) including sclerosing cholangitis (41.2% versus 19.6%, p = 0.075), autoimmune pancreatitis (64.7% versus 25.4%, p = 0.003), colitis (0.0% versus 3.9%, p = 0.407). The baseline laboratory findings revealed that less IgG4-RD complicating malignancy patients had eosinophilia (5.9% versus 31.4%, p = 0.022) than controls.

Related factors of malignancies in patients with IgG4-RD. Based on initial comparison results listed above, head and neck involvement, autoimmune pancreatitis and eosinophilia were related factors for having malignancies in IgG4-RD patients. As shown in Table 3, odds ratio were calculated by univariate analysis and we identified that head and neck involvement (OR 0.304, 95%CI 0.097–0.925, p = 0.041) and eosinophilia (OR 0.017, 95%CI 0.014–0.966, p = 0.046) were potentially negatively related to malignancies in patients with IgG4-RD and autoimmune pancreatitis (OR 5.359, 95%CI 1.651–17.939, p = 0.005) were positively related to malignancies in...
patients with IgG4-RD. Multivariate analysis confirmed that autoimmune pancreatitis (OR 6.230, 95%CI 1.559–24.907, \( p = 0.010 \)) was an independent risk factor for IgG4-RD patients developing malignancies. In contrast, eosinophilia (OR 0.094, 95%CI 0.010–0.883, \( p = 0.039 \)) was an independent protective factor from malignancy in patients with IgG4-RD.

**Treatment and prognosis.** The mean initial dosage of corticosteroids (equivalent to prednisone) was 40.1 ± 10.0 mg/d in IgG4-RD complicating malignancy patients comparing to 32.4 ± 17.5 mg/d in controls. Among the seventeen IgG4-RD complicating malignancy patients, ten (58.8%) patients received immunosuppressive agents, including cyclophosphamide (2, 11.8%), mycophenolate mofetil (2, 11.8%), azathioprine (2, 11.8%), igeratimod (2, 11.8%) leflunomide (1, 5.9%) and methotrexate (1, 5.9%). Sixteen patients underwent resection therapy, with one lymphoma received chemotherapy. During a median follow-up period of 61.4 ± 26.4 months, all patients with IgG4-RD and malignancies survived. Two IgG4-RD patients without malignancy in the control group died due to liver failure and respiratory failure caused by other comorbidities.

| Patient | Sex | Age | Age at | Age at | Serum IgG4 at | Organs involvements of IgG4-RD | Sites of malignancy |
|---------|-----|-----|--------|--------|---------------|------------------------------|-------------------|
|         |     |     | diagnosis of IgG4-RD | diagnosis of malignancy | (g/L) | (Organ with biopsy) | |
| P1      | F   | 59  | 58     | 54     | 1499          | Parotid gland*, salivary gland | Breast cancer      |
| P2      | M   | 74  | 66     | 68     | 10402         | Pancreas, bile duct, retroperitoneal fibrosis, kidney, prostate, lymph nodes | Rectal cancer      |
| P3      | M   | 46  | 42     | 40     | 2630          | Lacrimal gland, parotid gland | Lipoblastoma       |
| P4      | M   | 70  | 68     | 64     | 5780          | Pancreas, bile duct, lung, prostate, lymph nodes | Thyroid carcinoma  |
| P5      | F   | 62  | 61     | 61     | 11600         | Pancreas, bile duct, salivary gland*, periaortitis, lymph nodes, pituitary | Thyroid carcinoma  |
| P6      | M   | 72  | 68     | 68     | 3490          | Pancreas, bile duct, lymph nodes | Rectal cancer      |
| P7      | M   | 60  | 58     | 58     | 2410          | Pancreas, bile duct, lymph nodes | Renal cancer       |
| P8      | M   | 68  | 63     | 68     | 3520          | Pancreas, bile duct, retroperitoneal fibrosis, lung, kidney, artery, lymph nodes | Rectal cancer      |
| P9      | M   | 36  | 30     | 35     | 12400         | Pancreas, bile duct | Skin cancer         |
| P10     | M   | 52  | 49     | 52     | 10000         | Pancreas, parotid gland*, lacrimal gland, lung, prostate, lymph nodes | Thyroid carcinoma  |
| P11     | F   | 70  | 68     | 69     | 17300         | Parotid gland, lacrimal gland, salivary gland, sinus | Lung cancer        |
| P12     | M   | 82  | 79     | 79     | 58000         | Pancreas, lacrimal gland* | Colon cancer        |
| P13     | F   | 50  | 49     | 45     | 14300         | Uterus*, ovary | Ovarian carcinoma    |
| P14     | F   | 52  | 46     | 50     | 10000         | Parotid gland*, lacrimal gland | Breast cancer       |
| P15     | F   | 60  | 55     | 57     | 12500         | Pancreas, parotid gland, lacrimal gland, lymph nodes, sinus | Lymphoma           |
| P16     | M   | 42  | 37     | 40     | 7490          | Lung*, lymph nodes | Renal cancer         |
| P17     | M   | 71  | 68     | 69     | 415           | Pancreas*, bile duct | Prostate cancer      |

### Table 1. Baseline characteristic of IgG4-RD patients with malignancy.

![Flowchart of inclusion of patients with IgG4-RD and malignancy.](image)

Figure 1. Flowchart of inclusion of patients with IgG4-RD and malignancy.
Discussion

To our knowledge, the present study is the first to report reliable data of Chinese IgG4-RD patients complicating malignancies and describes the largest cohort of IgG4-RD patients. We demonstrated malignancy incidence and distributions in IgG4-RD patients. Clinical characteristics of IgG4-RD patients with malignancy were compared, and potential risk and protective factors for IgG4-RD patients with malignancy were detected. We also summarized the prognosis of these patients.

The question of whether IgG4-RD patients are at an increased risk of malignancy has not been fully answered yet. As shown in Fig. 2, two studies from Japan reported no significant increase in the incidence of malignancy in IgG4-RD patients. In contrast, other studies from Japan, the United States, the United Kingdom and South Korea have reported that IgG4-RD patients have a higher prevalence or incidence of malignancies. Similar to those studies, our study confirmed a total malignant SIR of 2.78 (95% CI 1.33–5.12) in Chinese patients.

When clinical physicians treat IgG4-RD patients, it is important to know what malignancy is most likely to occur. Our study reported that in Chinese IgG4-RD cohort, the most prevalent solid tumour was located in the gastrointestinal tract, followed by the thyroid, urinary system and breast. Different malignancy distributions were observed in studies from other countries, with the highest reported incidences of lung cancers, gastric cancers, and prostate cancers, respectively, which may be due to geographic differences. Only one lymphoma case out of

Table 2. Comparisons of baseline demographics, clinical features and laboratory findings in IgG4-RD patients with and without malignancy. IgG4-RD: IgG4-related disease; SD: standard deviation; EOS: eosinophil; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; IQR: interquartile range.
17 malignancies were observed in our study, whereas a South Korean cohort reported 4 lymphoma cases (out of 12 malignancies)\(^3\).

Chinese IgG4-RD-CA patients have distinct clinical features. In this study, they were more prone to have autoimmune pancreatitis (AIP) and less likely to have head and neck gland involvement. Moreover, eosinophilia was less common in IgG4-RD-CA patients than in controls. Of note, other risk factors were reported including DM by Hirano’s group\(^8\) and IgG4-RD onset age >65 years\(^8\). This difference might be due to selection of controls, and the results need to be confirmed by larger and prolonged observational studies. Previous study detected that the presence of AIP was more closely associated with extra-pancreatic cancer than pancreatic cancer itself\(^8,9,17–20\). And most cancer cases detected in AIP occur at or within a year of diagnosis\(^19\). These results are in line with our findings that AIP is a potential risk factor for complicating malignancies. K-ras gene mutations have been detected in the gastrointestinal tract in AIP patients, indicating pancreatic tissues of AIP patients might share similar immune responses with cancer\(^21\). Furthermore, cancer and pancreatic tissues of AIP patients with cancer share key immune responses leading to the enhancement of IgG4 antibody production\(^17\). These might contribute to the pathogenesis of AIP complicating with malignancies. Notably, we also found a potent independent protective indication for malignancy in IgG4-RD patients: eosinophilia. It was reported that a high proportion of patients have longstanding allergies, peripheral blood eosinophilia and serum IgE elevation and T helper type 2 responses was presumed to be pathogenic in IgG4-RD, which might indicate a close relationship between allergy and IgG4-RD\(^22\). Elevated serum IgE and peripheral eosinophilia may predict risk of flare after treatment, while a dominant eosinophilic infiltrate is not common in IgG4-RD involved organ\(^23\). In the present study, multivariate logistic regression analysis confirmed eosinophilia were significantly negative related to malignancy in IgG4-RD patients (OR 0.094, 95%CI 0.010–0.883, \(p = 0.039\)). This indicates the heterogenetic characteristics of IgG4-RD patients and subgroup analysis are needed\(^24\). No difference was observed between the serum IgG4 level between IgG4-RD patient with and without malignancies in this study. Prior findings demonstrated that mild elevation (within 1–2 upper limits of normal) of IgG4 has been observed in 5% to 15% of pancreatic carcinoma patients, and high levels of IgG4 were more specific for autoimmune pancreatitis (AIP)\(^25,26\). Controversially, Wallace\(^5\) and Asano\(^6\) reported that IgG4-RD patients with malignancy demonstrated a higher IgG4 serum level than IgG4-RD patients without malignancy. One possible explanation for the lower serum IgG4 levels in IgG4-RD-CA patients is that IgG4-RD, as a paraneoplastic syndrome, is able to induce limited elevations of IgG4 and atypical IgG4-related disease\(^6\). Additional studies evaluating the appropriate cut-off level of serum IgG4 concentrations affecting IgG4-RD prognosis and what kind of malignancies are more likely to accompany mild IgG4 elevation are required.

To our knowledge, no report has previously described the mortality and prognosis of IgG4-RD-CA patients. In the present study, during 61.4 ± 26.4 months of continuous follow-up, all IgG4 patients with malignancies survived. Although IgG4-RD patients had an increased incidence of malignance, the periodical follow-up and detailed examination of the recruited patients in our cohort might lead to an early detection and treatment of malignancy and improved the prognosis.

The pathophysiology of IgG4-RD complicating malignancy is still under investigation. It is well established that long-standing chronic inflammation plays a critical role in the development of cancer through the process of inflammation-associated carcinogenesis\(^27\). Our study showed that almost half of patients developed malignancies...
in the IgG4-RD background. Moreover, Asano et al. reported 12 patients experiencing malignancies in the same organ affected by IgG4-RD out of 27 IgG4-RD-CA patients. It could be because IgG4-RD causes sustained inflammation that may induce preferable cancerous microenvironments, which resembles the mechanism of lymphoma development in association with Sjögren’s syndrome. However, it has been reported that surgical resection of cancer was able to cause remission of IgG4-RD, indicating that IgG4-RD might be a type of para-neoplastic syndrome. Overall, it is still too early to draw a definitive conclusion of the pathogenesis of IgG4-RD and malignancies. Nevertheless, our study provides the critical information for physicians that IgG4-RD-affected organs should be carefully screened for potential malignancy occurrence during follow-up.

There are some limitations of this study. First, we only included consecutive patients from 2011 to 2018, and had not conducted an extensive long-term follow-up to the endpoint of death. Second, this is a single-center cohort study, and an increased number of patients should be continuously recruited. Third, this is a clinical observational study, and we did not investigate the detailed pathophysiology of these two disease entities, and further research in this field should receive more attention.

In conclusion, this prospective cohort study demonstrated that Chinese IgG4-RD patients have a 2.78-fold increased risk of having malignancy over a median of 61.4 months of follow-up. The most common malignancy site was the gastrointestinal tract. Autoimmune pancreatitis was identified as a potential risk factor for IgG4-RD patients having malignancy, while eosinophilia as protective indicators.

Received: 20 December 2019; Accepted: 27 February 2020;
Published online: 18 March 2020

References
1. Umehara, H. et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD). 2011. Mod. Rheumatol. 22, 21–30 (2012).
2. Zhang, W. & Stone, J. H. Management of IgG4-related disease. Lancet Rheumatol. 1, e55–e65 (2019).
3. Ahn, S. S., Song, J. J., Park, Y.-B. & Lee, S.-W. Malignancies in Korean patients with immunoglobulin G4-related disease. Int. J. Rheum. Dis. 20, 1028–1035 (2017).
4. Sekiguchi, H. et al. IgG4-Related Disease: Retrospective Analysis of One Hundred Sixty-Six Patients. Arthritis Rheumatol. 68, 2290–2299 (2016).
5. Wallace, Z. S., Wallace, C. J., Lu, N., Choi, H. K. & Stone, J. H. Association of IgG4-Related Disease With History of Malignancy. Arthritis Rheumatol. 68, 2283–2289 (2016).
6. Asano, J. et al. Association Between Immunoglobulin G4-Related Disease and Malignancy within 12 Years after Diagnosis: An Analysis after Longterm Followup. J. Rheumatol. 42, 2135–2142 (2015).
7. Inoue, D. et al. IgG4-related disease: dataset of 235 consecutive patients. Mod. Rheumatol. 94, e680 (2015).
8. Hirano, K. et al. Incidence of malignancies in patients with IgG4-related disease. Intern. Med. 53, 171–176 (2014).
9. Yamamoto, M. et al. Risk of malignancies in IgG4-related disease. Mod. Rheumatol. 22, 414–418 (2012).
10. Huggett, M. T. et al. Type 1 Autoimmune Pancreatitis and IgG4-Related Sclerosing Cholangitis Is Associated With Extrapancreatic Organ Failure, Malignancy, and Mortality in a Prospective UK Cohort. Am. J. Gastroenterol. 109, 1675–1683 (2014).
11. Lin, W. et al. Clinical characteristics of immunoglobulin G4-related disease: a prospective study of 118 Chinese patients. Rheumatol. 54, 1982–1990 (2015).
12. Wang, L. et al. Sex disparities in clinical characteristics and prognosis of immunoglobulin G4-related disease: a prospective study of 403 patients. Rheumatol. 58, 820–830 (2018).
13. Zhang, J. et al. Characterizing IgG4-related disease with 18F-FDG PET/CT: a prospective cohort study. Eur. J. Nucl. Med. Mol. Imaging 41, 1624–1634 (2014).
14. Deng, C. et al. Histopathological diagnostic value of the IgG4+/IgG+ ratio of plasmacytic infiltration for IgG4-related diseases: a PRISMA-compliant systematic review and meta-analysis. Mod. Rheumatol. 94, e579 (2015).
15. Chen, W., Zheng, R., Zeng, H. & Zhang, S. The updated incidences and mortalities of major cancers in China. 2011. Chin. J. Cancer 34, 502–507 (2015).
16. Zheng, R. et al. Estimates of cancer incidence and mortality in China. 2013[J]. Chin. J. Cancer 36(1), 66 (2017).
17. Shiokawa, M. et al. Risk of cancer in patients with autoimmune pancreatitis. Am. J. Gastroenterol. 108, 610–617 (2013).
18. Hart, P. A. et al. Risk of cancer in patients with autoimmune pancreatitis: a case-control study and review of the literature. Pancreas 43, 417–421 (2014).
19. Schneider, A. et al. Risk of Cancer in Patients with Autoimmune Pancreatitis: A Single-Center Experience from Germany. Digestion 95, 172–180 (2017).
20. Huggett, M. et al. Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extra-pancreatic organ failure, malignancy and mortality in a prospective UK cohort. Am. J. Gastroenterol. 109, 1675–83 (2014).
21. Kamisawa, T. et al. K-ras mutation in the major duodenal papilla and gastric and colonic mucosa in patients with autoimmune pancreatitis. J. Gastroenterol. 45, 771–778 (2010).
22. MSc, Z. S. W. M. et al. Immunoglobulin G4-related Disease. Clin. Chest Med. 40, 583–597 (2019).
23. Wallace, Z. S. et al. Predictors of disease relapse in IgG4-related disease following rituximab. Rheumatol. 55, 1000–1008 (2016).
24. Culever, L. et al. Increases in IgE, Eosinophils, and Mast Cells Can be Used in Diagnosis and to Predict Relapse of IgG4-Related Disease. Clin. Gastroenterol Hepatology 15, 1444–1452.e6 (2017).
25. Gupta, R. et al. Does autoimmune pancreatitis increase the risk of pancreatic carcinoma?: a retrospective analysis of pancreatic resections. Pancreas 42, 506–510 (2013).
26. Ghazale, A. et al. Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am. J. Gastroenterol. 102, 1646–1653 (2007).
27. Chiba, T., Marusawa, H. & Ushijima, T. Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology 143, 550–563 (2012).
28. Routsias, J. G. et al. Malignant lymphoma in primary Sjögren's syndrome._ An update on the pathogenesis and treatment. Semin. Arthritis Rheumatism 43, 178–186 (2013).
29. Hirano, K., Isayama, H., Tada, M. & Koke, K. Association between autoimmune pancreatitis and malignancy. Clin. J. Gastroenterol. 7, 200–204 (2014).

Acknowledgements
This work was supported by the National Natural Science Foundation of China (No. 81801633, 81373190, 81571587), Chinese Academy of Medical Sciences Young Medical Talent Award Fund (No. 2018RC320005), the CAMS Initiative for Innovative Medicine (2017-12M-3-001) and the National Key Research and Development Program of China (2016YFC0901500).
Author contributions
Dr. Hanqi Tang have made contributions to analysis and interpretation of data and made the figures and drafted the manuscript; Dr. Huaxia Yang have designed the study, drafted and revised the manuscript, and have approved the final version to be published. Dr. Wen Zhang have set up the cohort, designed the work and have approved the final version to be published. Dr. Panpan Zhang, Di Wu, Shangzhu Zhang, Jiuliang Zhao, Linyi Peng, Hua Chen, Yunyun Fei have made contributions to acquisition, summary and analysis the data. Dr. Xuan Zhang, Yan Zhao, Xiaofeng Zeng, Fengchun Zhang revised it critically for important intellectual content. All the authors approved the submitted manuscript and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to H.Y. or W.Z.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020